PFIZER INC. DL-_05
Commented by Armin Schulz on September 4th, 2026 | 07:35 CEST
From the Pill to the Dissolving Film and the Monthly Injection for Obesity: Novo Nordisk, BioNxt Solutions and Pfizer
Obesity treatment is undergoing a transformation. Following the initial success of GLP-1 medications, the next round is now underway. It is no longer just about efficacy, but also about the method of administration. Novo Nordisk was the first to launch the oral pill on the European market and is already testing lower maintenance doses. BioNxt Solutions is countering with oral dissolvable thin films (ODFs) that require neither a needle nor water. Pfizer, meanwhile, is focusing on a monthly ultra-long-acting GLP-1 derived through its acquisition of Metsera. Today we take a closer look at the strategies of Novo Nordisk, BioNxt Solutions and Pfizer.
Read
Commented by Lars Winter on August 26th, 2026 | 07:20 CEST
Money, Money, Money: RE Royalties, Aumann and Pfizer Put Dividend Investors in the Money
Dividends are far more than just a consolation prize during weak market phases. Profit distributions typically account for a large portion of a stock's total return. In addition, dividends generally fluctuate much less than earnings and share prices. A high yield alone, however, is not a seal of quality. It can also result from a sharp drop in the share price, an overextended payout ratio, or an impending cut. Many dividend enthusiasts therefore also seek reliability. The three selected dividend stocks cover different strategies: RE Royalties entices with a double-digit yield and the greatest upside potential, but also carries the highest risk. Aumann, on the other hand, is a short-term speculative play offering a generous special dividend, largely financed by its well-stocked cash reserves. Pfizer, in contrast, offers the lowest yield of the trio but boasts the longest and most reliable dividend history. We take a closer look at these stocks.
Read
Commented by Armin Schulz on August 12th, 2026 | 07:05 CEST
Three Paths to the Cancer Drug of the Future: BioNTech, Vidac Pharma, and Pfizer Under the Oncology Spotlight
Oncology has become the most dynamic field of innovation in the pharmaceutical industry. The focus is not on finding a miracle cure, but rather on developing highly precise, personalized therapies that target tumors at the molecular level. For investors, this market, which is growing at double-digit rates, is attractive in the long term. While there is a world of difference between established corporations and agile biotech companies with groundbreaking technology platforms, both offer enormous potential for value appreciation. Today, we take a look at three companies that are aiming to discover the next blockbuster drug: BioNTech, Vidac Pharma and Pfizer.
Read
Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST
"Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future
Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?
Read
Commented by Stefan Bode on July 24th, 2026 | 08:40 CEST
Opportunities & Risks in Q2 Earnings: Almonty Industries, BioNTech, Danaher, Pfizer, and Sartorius
Global equity markets remain highly dynamic, and the fundamental backdrop has changed rapidly in recent quarters. In today's report, we examine three compelling investment stories at critical turning points. We take a closer look at former pandemic-era pharmaceutical high-flyers that must now navigate new tariffs as they shift their focus toward cancer therapies. We also analyze a geopolitically indispensable producer of a critical raw material that is benefiting significantly from efforts to secure Western supply chains. Finally, we turn to the bioprocessing sector, where upcoming quarterly earnings could determine the industry's direction following recent market turbulence. Find out where the most attractive opportunities, and the key risks, may lie.
Read
Commented by Armin Schulz on July 9th, 2026 | 07:35 CEST
From Injection Blockbusters to an Oral Future: An Analysis of Novo Nordisk, BioNxt Solutions, and Pfizer in This Race
The weight-loss injection has fundamentally transformed the pharmaceutical industry and set in motion a business with billion-dollar potential, but this initial gold rush is over. The industry is undergoing a disruptive transformation in which more convenient oral alternatives are increasingly replacing the unpleasant injection. This development is shifting the balance of power, giving latecomers a historic opportunity while the market leaders must defend their dominance. The battle for power in obesity treatment has begun anew. Which company will take the lead in the next phase? Today, we take a closer look at Novo Nordisk, BioNxt Solutions, and Pfizer.
Read
Commented by Armin Schulz on June 24th, 2026 | 08:30 CEST
Cancer remains the hottest bet in the pharmaceutical market: Bayer, Vidac Pharma, and Pfizer are competing for the next generation of therapies
The oncology market is the most dynamic segment of the pharmaceutical industry. While global heavyweights are positioning their multibillion-dollar pipelines, a small biotech company is banking on a scientific approach that directly targets the metabolism of tumour cells. For investors, the key question is whether the future of cancer treatment will be defined by broad-based therapies, targeted antibody-drug conjugates, or precise interventions at the cellular metabolic level. The differing approaches taken by Bayer, Vidac Pharma, and Pfizer promise to set the course not only medically but also financially for the coming decade.
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read